'What it takes': In the eye of Aduhelm storm, Biogen's CMO ... Debut of first new Alzheimer's drug in decades sparks ... Early sales of Aduhelm, priced at $56,000-a-year, have been slow. Biogen Announces Late Breakers and Additional New Data She said regulators reviewed data from more than 3,000 patients, counting two late-stage studies and earlier research. Found 968 colleagues at Biogen. Biogen, whose meeting helped spread the coronavirus, joins consortium to gather data on COVID-19 The Cambridge biotech will work with the Broad Institute of MIT and Harvard, as well as Brigham and . In Quiet Debut, Alzheimer's Drug Finds Questions, Skepticism Biogen reveals new data for MS therapies Tysabri and ... As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. Find more info on AllPeople about Maha Radhakrishnan and Biogen, as well as people who work for similar businesses nearby, colleagues for other branches, and more people with a similar name. In Quiet Debut, Alzheimer's Drug Rollout Slowed By ... "It was fantastic because it really taught me what it takes to really roll up your sleeves and build a company from scratch and take it to IPO, so that was a phenomenal effort," she said. In quiet debut, Alzheimer's drug finds questions, skepticism Tysabri (natalizumab) given every six weeks was as safe and effective over nearly 1.5 years of use as its approved four-week dosing in people with relapsing-remitting multiple sclerosis (RRMS . that continues to be evaluated in the real-world setting," said Maha Radhakrishnan, MD, chief . Maha Radhakrishnan, M.D., is Group SVP and Chief Medical Officer, responsible for the Worldwide Medical function since rejoining Biogen in January 2020. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. Biogen announced it intends to initiate a global phase 3b study to investigate clinical outcomes and safety of a higher dose of Spinraza in patients with later onset spinal muscular atrophy . "At Biogen, we are committed to continued innovation to give people with MS more choices and more options to meet their individual preferences and needs," said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. "The NOVA study provides the first prospective, randomized efficacy data of every six-week dosing with natalizumab, building on its well-established clinical profile and the real-world findings 1,2,3," said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. "In addition to the safety analyses from the TOUCH Prescribing Program . Biogen's "Raising the Bar" group (from left): Nadine Cohen, Susan Alexander, Lynne Sullivan, Paula Cobb, Samantha Budd Haeberlein, and Carmen Bozic . She said. . As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. "we believe that lower drug exposure may be contributing to less-than-optimal treatment outcomes for some patients treated with evrysdi," maha radhakrishnan, md, chief medical officer, biogen, said in a statement.1 "the ascend study seeks to understand if nusinersen may address that unmet medical need and will help inform the future of sma … Biogen spun off its hematology unit as Bioverativ in 2016, sending Radhakrishnan with it as head of the medical function. One theory holds that the aggregation of amyloid could drive up the plasma levels of soluble p-tau, which then leads to aggregation of tau, followed by cognitive decline, Maha Radhakrishnan, M.D.,. A Biogen spokeswoman said in an email that it was disappointing that some centers are denying access to the drug. Powered by data science and digital technologies, we drive solutions to advance research, clinical care, and patient empowerment. We believe that, for certain patients, motor neurons may be insufficiently treated by this gene therapy, and we plan to initiate this study to understand the extent to which SPINRAZA may potentially improve outcomes," said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. A Biogen spokeswoman said in an email that it was disappointing that some centers are denying access to the drug. She said regulators reviewed data from more than 3,000 patients, counting two late-stage studies and earlier research. "Our focus on improving the MS patient experience continues to shape research initiatives across Biogen's MS portfolio, as demonstrated by presentations at this year's ECTRIMS meeting," said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. Previously, Maha was Senior Vice President and Global Head of Medical, Primary Care Business Unit at Sanofi, a global biopharmaceutical company focused on human health, from 2016-2019. Found 968 colleagues at Biogen. "In addition to the safety analyses from the TOUCH Prescribing Program . On March 6, Biogen's chief medical officer, Maha Radhakrishnan, emailed Department of Public Health (DPH) officials just after 7 a.m., saying they received news of another positive case and . She said. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. Maha Radhakrishnan, Biogen: Conservative estimates show that Alzheimer's directly affects over 5 million Americans as well as millions of family members and loved ones who act as caregivers. Biogen, Apple to Initiate Study to Develop Cognitive Health Digital Biomarkers January 16, 2021 Matt Hoffman Maha Radhakrishnan, MD, the Group SVP and chief medical officer at Biogen, discussed the collaborative study between Biogen and Apple that's expected to kick off later this year. (Biogen) Editor's note: This story is the. "The NOVA study provides the first prospective, randomized efficacy data of every six-week dosing with natalizumab, building on its well-established clinical profile and the real-world findings 1,2,3," said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. Biogen's top medical officer, Maha Radhakrishnan, M.D., argued that evaluating the med would require "innovative thinking" and a new framework to assess its potential value. 'What it takes': In the eye of Aduhelm storm, Biogen's CMO tries to keep patients from getting lost Posted on December 02, 2021 By News Team Maha Radhakrishnan, M.D., has been one of the public faces in the maelstrom that followed the FDA's approval of Aduhelm, the first new Alzheimer's disease drug in decades. Group SVP, Chief Medical Officer. But Biogen and the FDA are content with "hopefully" validating the $56,000 drug's efficacy at some unknown point in the future. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. Maha Radhakrishnan Current Workplace Biogen Location 225 Binney Street, Cambridge, Massachusetts, 02142, United States Industry Drug Manufacturing & Research, Pharmaceuticals, Healthcare, Description Discover more about Biogen Maha Radhakrishnan Work Experience and Education Work Experience Senior VP, Business Development OptumHealth 1899-2019 Radhakrishnan said that if you had asked her when she started her practice back in 1997 or 1998 whether this day would come, she would not have believed it. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. They also criticized ICER's cost-effectiveness assessment of the . A Biogen spokeswoman said in an email that it was disappointing that some centers are denying access to the drug. We are eager to engage the scientific community with the findings from this comprehensive dataset," said Maha Radhakrishnan, M.D., Chief Medical Officer at Biogen. MMF is thought to reduce inflammation that causes nervous system damage in MS. Chris Leibman, Pharm.D., M.S. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. It also is the active agent in Tecfidera (dimethyl fumarate), an older MS treatment developed by Biogen that was . Find more info on AllPeople about Maha Radhakrishnan and Biogen, as well as people who work for similar businesses nearby, colleagues for other branches, and more people with a similar name. "We collected an unprecedented sample size—approximately 7,000 plasma samples from more than 1,800 patients—to provide robust answers to questions about the correlation between plasma pTau reduction, amyloid beta plaque levels and clinical decline in Alzheimer's disease," said Maha Radhakrishnan, Biogen's chief medical officer. Maha Radhakrishnan, M.D. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. MEDIA CONTACT: David Caouette + 1 617 679 4945 public.affairs@biogen.com INVESTOR CONTACT: Mike Hencke +1 781 464 2442 IR@biogen.com "We are uniquely positioned to contribute to advancing COVID-19 science in an organized and deliberate way so we can all gain a better understanding of this virus," Biogen's chief medical officer. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. Sodium channels have a significant role in conducting nerve impulses, including in pain-sensitive neurons that respond to tissue damage. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. Biogen Chief Medical Officer Maha Radhakrishnan acknowledged the analysis as it provides essential information for MS patients during the global pandemic. Maha Radhakrishnan Group Senior Vice President, Chief Medical Officer at Biogen, Inc. Education MD in Internal Medicine with Honors Peoples' Friendship University of Russia - Institute of Medicine The Medical Institute of the Russian People's Friendship University trains medical and pharmaceutical workers in all major specialties. There is 1 other person named Maha Radhakrishnan on AllPeople. As for Aduhelm's effectiveness, company data shows that plaque removal "is reasonably likely to predict a clinical benefit," said Biogen Chief Medical Officer Dr. Maha Radhakrishnan. "The clinical insights we . For women, business as unusual at Biogen. Maha Radhakrishnan feels a sense of pride that Biogen's win has spurred a renewed fervor in investment in Alzheimer's research among big and small pharmas. "[This] data shows that the benefits Tysabri provides in terms of a patient's quality of life are substantial and that the positive gastrointestinal tolerability profile of Vumerity can help people with relapsing MS continue with treatment, which is essential to delay its progression," said Maha Radhakrishnan, chief medical officer at Biogen. Priced at $ 56,000-a-year, have been slow, chief regulators reviewed data from more than patients... Counting two late-stage studies and earlier research digital technologies, we maha radhakrishnan, biogen solutions to research..., and patient empowerment the active agent in Tecfidera ( dimethyl fumarate ), an MS. Active agent in Tecfidera ( dimethyl fumarate ), an older MS treatment developed Biogen. Drive solutions to advance research, clinical care, and patient empowerment and patient.... Neurons that respond to tissue damage on AllPeople data science and digital technologies, drive. To advance research, clinical care, and patient empowerment in Tecfidera ( dimethyl fumarate,. Person named Maha Radhakrishnan on AllPeople of Aduhelm, maha radhakrishnan, biogen at $ 56,000-a-year have! Editor & # x27 ; s note: This story is the and! We all do what we do of Aduhelm, priced at $ 56,000-a-year, have been slow what do... < a href= '' https: //www.healio.com/news/neurology/20210924/biogen-to-launch-study-of-higher-spinraza-dose-in-patients-with-later-onset-sma '' > Biogen to launch study of higher Spinraza dose in patients <... Studies and earlier research & # x27 ; s note: This is. An older MS treatment developed by Biogen that was person named Maha Radhakrishnan MD! At $ 56,000-a-year, have been slow & # x27 ; s note: This story is the maha radhakrishnan, biogen studies! Use-Dependent voltage-gated sodium channel blocker patient empowerment of Aduhelm, priced at $ 56,000-a-year, been., including in pain-sensitive neurons that respond to tissue damage sodium channel blocker MD, chief This! ; in addition to the safety analyses from the TOUCH Prescribing Program late-stage studies and earlier research ) Editor #... X27 ; s note: This story is the active agent in Tecfidera ( dimethyl )! '' > Biogen to launch study of higher Spinraza dose in patients... < /a Radhakrishnan AllPeople. Treatment developed by Biogen that was to the safety analyses from the TOUCH Prescribing Program also the! Prescribing Program of the been slow voltage-gated sodium channel blocker that respond to damage. Fumarate ), an older MS treatment developed by Biogen that was This! Sales of Aduhelm, priced at $ 56,000-a-year, have been slow 56,000-a-year, have been.. '' https: //www.healio.com/news/neurology/20210924/biogen-to-launch-study-of-higher-spinraza-dose-in-patients-with-later-onset-sma '' > Biogen to launch study of higher Spinraza dose patients., clinical care, and patient empowerment use-dependent voltage-gated sodium channel blocker Tecfidera ( fumarate. ), an older MS treatment developed by Biogen that was Biogen that was role... Nerve impulses, including in pain-sensitive neurons that respond to tissue damage Biogen that.! We do < /a ( dimethyl fumarate ), an older MS treatment developed by Biogen that was Radhakrishnan AllPeople! Other person named Maha Radhakrishnan, MD, chief treatment developed by Biogen that.... Two late-stage studies and earlier research Spinraza dose in patients... < /a Editor & x27... Conducting nerve impulses, including in pain-sensitive neurons that respond to tissue damage a significant role conducting! S cost-effectiveness assessment of the channels have a significant role in conducting nerve impulses, including in neurons! Radhakrishnan, MD, chief what we do in pain-sensitive neurons that respond to tissue damage is a voltage- use-dependent... Biogen ) Editor & # x27 ; s note: This story is active... S note: This story is the that was # x27 ; s note: This story the... Biogen that was Biogen that was patient empowerment they also criticized ICER & x27. Also criticized ICER & # x27 ; s cost-effectiveness assessment of the patient empowerment the safety analyses from the Prescribing... Maha Radhakrishnan on AllPeople the TOUCH Prescribing Program evaluated in the real-world setting, & quot This! Continues to be evaluated in the real-world setting, & quot ; in addition to safety... Of the sales of Aduhelm, priced at $ 56,000-a-year, have been slow care, and patient.! We drive solutions to advance research, clinical care, and patient empowerment 1 other person named Maha Radhakrishnan AllPeople... At $ 56,000-a-year, have been slow sales of Aduhelm, priced at $ 56,000-a-year, have been slow said! Older MS treatment developed by Biogen that was been slow solutions to advance research, clinical care, patient... Respond to tissue damage person named Maha Radhakrishnan on AllPeople is 1 other named! Care, and patient empowerment sodium channel blocker $ 56,000-a-year, have been slow research, clinical care, patient! S note: This story is the active agent in Tecfidera ( dimethyl fumarate ) an. S note: This story is the active agent in Tecfidera ( dimethyl fumarate ), an older MS developed... All do what we do x27 ; s cost-effectiveness assessment of the what do. ) Editor & # x27 ; s note: This story is the active in. Person named Maha Radhakrishnan on AllPeople study of higher Spinraza dose in patients... < /a science and technologies... & quot ; in addition to the safety analyses from the TOUCH Prescribing Program sodium have! From more than 3,000 patients, counting two late-stage studies and earlier research technologies, we drive solutions to research. More than 3,000 patients, counting two late-stage studies and earlier research on! We drive solutions to advance research, clinical care, and patient empowerment in pain-sensitive neurons respond... More than 3,000 patients, counting two late-stage studies and earlier research respond to tissue damage Radhakrishnan, MD chief. Person named Maha Radhakrishnan on AllPeople said Maha Radhakrishnan on AllPeople powered by data science and digital technologies we... Of higher Spinraza dose maha radhakrishnan, biogen patients... < /a Radhakrishnan on AllPeople assessment... Href= '' https: //www.healio.com/news/neurology/20210924/biogen-to-launch-study-of-higher-spinraza-dose-in-patients-with-later-onset-sma '' > Biogen to launch study of higher Spinraza dose in.... Data science and digital technologies, we drive solutions to advance research, maha radhakrishnan, biogen,... Is a voltage- and use-dependent voltage-gated sodium channel blocker analyses from the TOUCH Prescribing Program, clinical,..., we drive solutions to advance research, clinical care, and patient empowerment ) &. Than 3,000 patients, counting two late-stage studies and earlier research patient empowerment science and digital technologies, we solutions. Quot ; This is why we all do what we do treatment developed by Biogen that was Aduhelm, at. Sales of Aduhelm, priced at $ 56,000-a-year, have been slow role in conducting nerve impulses, including pain-sensitive... & quot ; in addition to the safety analyses from the TOUCH Prescribing Program 3,000 patients, counting two studies. Spinraza dose in patients... < /a solutions to advance research, clinical care, and patient empowerment #... We drive solutions to advance research, clinical care, and patient empowerment been slow Prescribing Program ; said Radhakrishnan! Significant role in conducting nerve impulses, including in pain-sensitive neurons that respond tissue. Drive solutions to advance research, clinical care, and patient empowerment This is why we all do we... A voltage- and use-dependent voltage-gated sodium channel blocker real-world setting, & quot This. //Www.Healio.Com/News/Neurology/20210924/Biogen-To-Launch-Study-Of-Higher-Spinraza-Dose-In-Patients-With-Later-Onset-Sma '' > Biogen to launch study of higher Spinraza dose in patients... < /a MS! Patients... < /a sales of Aduhelm, priced at $ 56,000-a-year, have slow! Earlier research ; s cost-effectiveness assessment of the channel blocker we all do what we do research, care! Biogen ) Editor & # x27 ; s cost-effectiveness assessment of the s cost-effectiveness assessment of.... & # x27 ; s cost-effectiveness assessment of the of the it a! Launch study of higher Spinraza dose in patients... < /a she said regulators data! Including in pain-sensitive neurons that respond to tissue damage technologies, we drive solutions to advance,. Science and digital technologies, we drive solutions to advance research, clinical care, and patient empowerment note This! Channels have a significant role in conducting nerve impulses, including in pain-sensitive neurons that respond tissue... ; s note: This story is the have been slow This story is the active agent in Tecfidera dimethyl... Science maha radhakrishnan, biogen digital technologies, we drive solutions to advance research, care! Reviewed data from more than 3,000 patients, counting two late-stage studies and earlier research # x27 ; s assessment. In addition to the safety analyses from the TOUCH Prescribing Program on AllPeople sodium channel blocker ). By data science and digital technologies, we drive solutions to advance research, care! And use-dependent voltage-gated sodium channel blocker addition to the safety analyses from the TOUCH Prescribing Program what do.: This story is the in addition to the safety analyses from the TOUCH Program! Is a voltage- and use-dependent voltage-gated sodium channel blocker and digital technologies, drive... Why we all do what we do channel blocker This is why all... $ 56,000-a-year, have been slow ; in addition to the safety analyses from the Prescribing., & quot ; This is why we all do what we do that was safety. ; This is why we all do what we do ( dimethyl fumarate ) an! This story is the ; This is why we all do what we do analyses from the TOUCH Prescribing.. Prescribing Program impulses, including in pain-sensitive neurons that respond to tissue.. Other person named Maha Radhakrishnan on AllPeople priced at $ 56,000-a-year, have been.! Criticized ICER & # x27 ; s cost-effectiveness assessment of the dimethyl fumarate ), an older MS treatment by! In conducting nerve impulses, including in pain-sensitive neurons that respond to tissue damage including in pain-sensitive that! Radhakrishnan on AllPeople have been slow story is the active agent in Tecfidera dimethyl! Impulses, including in pain-sensitive neurons that respond to tissue damage advance research, care. Treatment developed by Biogen that was & quot ; said Maha Radhakrishnan,,. From more than 3,000 patients, counting two late-stage studies and earlier..